Literature DB >> 17052812

Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.

Gabriela Minigo1, Anja Scholzen, Choon K Tang, Jennifer C Hanley, Martha Kalkanidis, Geoffrey A Pietersz, Vasso Apostolopoulos, Magdalena Plebanski.   

Abstract

DNA formulations provide the basis for safe and cost efficient vaccines. However, naked plasmid DNA is only poorly immunogenic and new effective delivery strategies are needed to enhance the potency of DNA vaccines. In this study, we present a novel approach for the delivery of DNA vaccines using inert poly-L-lysine (PLL) coated polystyrene particles, which greatly enhance DNA immunogenicity. Intradermal injection of plasmid DNA encoding for chicken egg ovalbumin (OVA) complexed with PLL-coated polystyrene nanoparticles induced high levels of CD8 T cells as well as OVA-specific antibodies in C57BL/6 mice and furthermore inhibited tumour growth after challenge with the OVA expressing EG7 tumour cell line. Importantly, vaccine efficacy depended critically on the size of the particles used as well as on the presence of the PLL linker. Our data show that PLL-coated polystyrene nanoparticles of 0.05 microm but not 0.02 microm or 1.0 microm in diameter are highly effective for the delivery of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052812     DOI: 10.1016/j.vaccine.2006.09.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

3.  High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine.

Authors:  Jeremy S Blum; W Mark Saltzman
Journal:  J Control Release       Date:  2008-04-16       Impact factor: 9.776

Review 4.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 5.  Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.

Authors:  Alvin J Mukalel; Rachel S Riley; Rui Zhang; Michael J Mitchell
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

6.  In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines.

Authors:  Jaeyun Kim; David J Mooney
Journal:  Nano Today       Date:  2011-10       Impact factor: 20.722

Review 7.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

Review 8.  Current understanding of interactions between nanoparticles and the immune system.

Authors:  Marina A Dobrovolskaia; Michael Shurin; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 9.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

10.  A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.

Authors:  Stephen A Kaba; Clara Brando; Qin Guo; Christian Mittelholzer; Senthilkumar Raman; David Tropel; Ueli Aebi; Peter Burkhard; David E Lanar
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.